A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor‐Positive Advanced Breast Cancer

[1]  World Cancer Research Fund International , 2018, The Grants Register 2019.

[2]  P. Marchetti,et al.  Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective. , 2017, Breast.

[3]  A. Tutt,et al.  3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Ellis,et al.  Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial , 2016, The Lancet.

[5]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[6]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[7]  M. de Boer,et al.  Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? , 2015, British Journal of Cancer.

[8]  D. Riseberg.  Treating Elderly Patients With Hormone Receptor–Positive Advanced Breast Cancer , 2015, Clinical Medicine Insights. Oncology.

[9]  Karla Unger-Saldaña,et al.  Challenges to the early diagnosis and treatment of breast cancer in developing countries. , 2014, World journal of clinical oncology.

[10]  Vered Stearns,et al.  Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. de Boer,et al.  Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome , 2013, Breast Cancer Research and Treatment.

[12]  G. Hortobagyi,et al.  Survival differences among women with de novo stage IV and relapsed breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  G. Viale,et al.  Axillary lymph node involvement in women with breast cancer: does it depend on age? , 2010, Clinical breast cancer.

[14]  O. Dekkers,et al.  Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients , 2010, Breast Cancer Research and Treatment.

[15]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[16]  A. Tutt,et al.  3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  K. Kuroi,et al.  Comparison of outcomes between women with de novo stage IV and relapsed breast cancer. , 2014, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[18]  April Fritz,et al.  International Classification of Diseases for Oncology: ICD-0. , 2000 .

[19]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.